Drug
ruxolitinib
Marketed as JAKAFI XR, OPZELURA.
Generic name
ruxolitinib
Brand names
JAKAFI XR, OPZELURA
First FDA approval
2021-09-21
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA217180 | JAKAFI XR | 2026-05-01 | INCYTE CORP |
| NDA215309 | OPZELURA | 2021-09-21 | INCYTE CORP |
Manufacturers
INCYTE CORP
Frequently asked questions
When was ruxolitinib FDA approved?
Earliest FDA approval on record: 2021-09-21.
What brand names are sold as ruxolitinib?
JAKAFI XR, OPZELURA.
Sources
Appeal a ruxolitinib denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com